MEDIROM Healthcare (MRM) Fundamental Analysis: Revenue, Earnings & Valuation

6.82 / 10

Outperform

Fundamental analysis rates the company Outperform, scoring 6.8/10. Strengths include a 26.3% YoY rise in diluted EPS, solid inventory turnover (10.17 days) and a robust total‑assets growth weight (0.78). Weaknesses are a –18.1% profit YoY decline and negative cash‑flow weight, tempering optimism.

Analysis Checks(1/5)

Total assets (growth rate compared to beginning of year %)

Value-1.17

Score3/3

Weight78.44%

1M Return3.14%

Total profit (YoY growth rate %)

Value-18.14

Score0/3

Weight-1.69%

1M Return-0.08%

Net cash flow from operating activities (YoY growth rate %)

Value55.21

Score0/3

Weight-15.26%

1M Return-0.76%

Diluted earnings per share (YoY growth rate %)

Value26.30

Score1/3

Weight18.12%

1M Return0.82%

Inventory turnover days

Value10.17

Score1/3

Weight20.38%

1M Return0.90%

Is MRM undervalued or overvalued?

MRM scores 6.82/10 on fundamentals and holds a Discounted valuation at present. Backed by its -81.90% ROE, -0.48% net margin, -39.75 P/E ratio, 2.59 P/B ratio, and 579.93% earnings growth, these metrics solidify its Outperform investment rating.